Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gastrointestinal Neoplasms 2Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 5S 1 (combination) 4Irinotecan 4pembrolizumab 3IFL protocol 3Fluorouracil 3Bevacizumab 3amminedichloro(2-methylpyridine)platinum(II) 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2MLN 8237 2Leucovorin 2Gemcitabine 2Folfox protocol 2Fecal Microbiota Transplantation 2Drug Therapy 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Capecitabine 2CGX1321 2ulixertinib 1tivozanib 1titanium silicide 1tislelizumab 1sodium thiosulfate 1sacituzumab govitecan 1remune 1plecanatide 1phosphatidyltransferase, Clostridium butyricum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Gastrointestinal Neoplasms × CGX1321 × Clear all
NCT02675946 2022-01-26

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Curegenix Inc.

Phase 1 Unknown
72 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT03507998 2020-07-24

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Curegenix Inc.

Phase 1 Unknown
39 enrolled
Gastrointestinal

Bile Duct Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡